Theravance Biopharma Inc (0TB) - Total Liabilities

Latest as of September 2025: €182.78 Million EUR ≈ $213.69 Million USD

Based on the latest financial reports, Theravance Biopharma Inc (0TB) has total liabilities worth €182.78 Million EUR (≈ $213.69 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Theravance Biopharma Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Theravance Biopharma Inc - Total Liabilities Trend (2014–2024)

This chart illustrates how Theravance Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 0TB current and non-current assets.

Theravance Biopharma Inc Competitors by Total Liabilities

The table below lists competitors of Theravance Biopharma Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Cablevision Holding SA BA:CVH	Argentina	AR$9.10 Trillion
Tian Jin Motor Dies Co Ltd SHE:002510	China	CN¥3.51 Billion
Nesco Limited NSE:NESCO	India	Rs-29.96 Billion
HIT Welding Industry Co. Ltd. SHE:301137	China	CN¥958.85 Million
Heritage Commerce Corp NASDAQ:HTBK	USA	$5.06 Billion
Adlai Nortye Ltd. American Depositary Shares NASDAQ:ANL	USA	$42.76 Million
Anhui Sierte Fertilizer Industry Ltd Co SHE:002538	China	CN¥1.02 Billion
Abacus Life Inc. NASDAQ:ABL	USA	$479.34 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Theravance Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Theravance Biopharma Inc to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	9.48	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.79	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.44	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Theravance Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Theravance Biopharma Inc (2014–2024)

The table below shows the annual total liabilities of Theravance Biopharma Inc from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	€178.62 Million ≈ $208.82 Million	+5.69%
2023-12-31	€169.00 Million ≈ $197.58 Million	+2.06%
2022-12-31	€165.60 Million ≈ $193.60 Million	-76.79%
2021-12-31	€713.39 Million ≈ $834.03 Million	-7.69%
2020-12-31	€772.81 Million ≈ $903.49 Million	+22.15%
2019-12-31	€632.67 Million ≈ $739.65 Million	+3.41%
2018-12-31	€611.82 Million ≈ $715.29 Million	+87.55%
2017-12-31	€326.22 Million ≈ $381.39 Million	+12.87%
2016-12-31	€289.02 Million ≈ $337.90 Million	+406.60%
2015-12-31	€57.05 Million ≈ $66.70 Million	+18.90%
2014-12-31	€47.98 Million ≈ $56.10 Million	--

About Theravance Biopharma Inc

F:0TB Germany Biotechnology

Market Cap

$864.92 Million

€739.82 Million EUR

Market Cap Rank

#9748 Global

#1199 in Germany

Share Price

€14.60

Change (1 day)

+0.00%

52-Week Range

€11.60 - €17.50

All Time High

€38.30